|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 USD | +0.75% |
|
-1.47% | +8.06% |
| Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
| Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
Akebia Therapeutics, Inc. provided revenue guidance for the year 2024. The company expected Auryxia net product revenue growth in 2024, with a quarterly revenue cadence that is similar to 2023.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.06% | 281M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
AKEBIA THERAPEUTICS, INC. 
